View Older Stories View More Recent Stories

Apr 1, 2026 07:05AM Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Mar 31, 2026 07:30AM CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma

Mar 30, 2026 08:38PM Form SCHEDULE 13G Xencor Inc Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 30, 2026 08:32PM Form SCHEDULE 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 30, 2026 08:01AM Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 27, 2026 09:00AM Navigator Medicines Advances NAV-240 into Phase 2a and NAV-242 into the Clinic, Supported by New Positive Data Presented at American Academy of Dermatology (AAD) Annual Meeting 2026

Mar 27, 2026 08:02AM OnKure raises $150 million to advance cancer treatment programs

Mar 27, 2026 08:00AM OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

Mar 26, 2026 04:05PM SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update

Mar 26, 2026 04:05PM Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Mar 26, 2026 07:30AM Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics, Announces Oversubscribed $89 Million Series B Financing to Advance Pipeline into Clinical Trials

Mar 25, 2026 04:05PM Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Mar 24, 2026 07:02AM Karyopharm raises $30 million in private placement with RA Capital

Mar 24, 2026 07:01AM Karyopharm Announces $30 Million Private Placement with RA Capital

Mar 23, 2026 04:28PM Form SCHEDULE 13D/A Acrivon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 23, 2026 04:26PM Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 20, 2026 04:13PM Form SCHEDULE 13G Equillium, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 18, 2026 06:00AM Ovid Therapeutics prices $60 million private placement for drug development

Mar 18, 2026 06:00AM Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Mar 17, 2026 06:50PM Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 17, 2026 04:36PM Form SCHEDULE 13D/A Acumen Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 16, 2026 04:15PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 16, 2026 06:30AM Acumen Pharmaceuticals raises $35.75 million in private placement

Mar 16, 2026 06:30AM Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Mar 13, 2026 04:45PM Network 1 Reports 2025 Year End Financial Results

Mar 13, 2026 08:01AM Equillium raises $35 million from RA Capital Management

Mar 13, 2026 08:00AM Equillium Announces $35 Million Financing with RA Capital Management

Mar 12, 2026 08:00AM Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

Mar 11, 2026 04:43PM Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 10, 2026 04:39PM Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 9, 2026 07:05AM Relmada Therapeutics raises $160 million in oversubscribed private placement

Mar 9, 2026 07:05AM Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Mar 6, 2026 08:31AM Solid Biosciences raises $240 million in private placement

Mar 6, 2026 08:31AM Solid Biosciences Announces Oversubscribed $240 Million Private Placement

Mar 5, 2026 07:00AM NexCure, Inc. Launches with $19 Million Series A Financing to enable CAR-T and other advanced treatment delivery in community outpatient settings

Mar 5, 2026 07:00AM Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Million

Mar 3, 2026 08:00AM T-knife Therapeutics Announces Authorization of Clinical Trial Application for TK-6302, A Multi-Armored, CRISPR based T cell Therapy for Solid Tumors

Mar 2, 2026 04:25PM Form SCHEDULE 13D/A Bicara Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 2, 2026 08:01AM Rallybio and Candid Therapeutics announce merger agreement

Mar 2, 2026 08:00AM Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Feb 26, 2026 06:30AM Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Feb 24, 2026 07:30AM Slate Medicines Launches with $130 Million Series A Financing to Advance Anti-PACAP Therapies for the Prevention of Migraine and Other Headache Disorders

Feb 18, 2026 08:01AM Sensei Biotherapeutics acquires Faeth Therapeutics for $200 million

Feb 18, 2026 08:00AM Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Feb 17, 2026 07:29PM Form SCHEDULE 13D/A Evommune, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 17, 2026 07:22PM Form SCHEDULE 13D SpyGlass Pharma, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 17, 2026 04:46PM Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 17, 2026 04:44PM Form SCHEDULE 13G/A Surrozen, Inc./DE Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 17, 2026 04:42PM Form SCHEDULE 13G/A RHYTHM PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 17, 2026 04:41PM Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.

View More Recent Stories View Older Stories